Keynote Speakers

Dr. Baochi Liu, Professor

Shanghai Publical Health Clinical Center, Fudan University, Shanghai, China

Biography: Dr. Baochi Liu graduated from Henan Medical College in 1983. He served as the chairman of henan Province public Health Emergency Medical Treatment Expert Committee, participated in the Chinese medical team to Zambia, and served as the chief medical officer of China-Zambia Friendship Hospital. In 2008, he was introduced to Shanghai Public Health Clinical Center as director of surgery. Led the surgical team to perform surgical treatment for more than 2000 patients with HIV infection combined with surgical diseases, and proposed surgical risk score for HIV infection. Autologous bone marrow cell therapy for AIDS complicated with decompensated cirrhosis achieved good efficacy, precise intrahepatic portal infusion of autologous bone marrow nucleated cells guided by original B-ultrasound for cirrhosis, and precise pancreas transplantation of bone marrow nucleated cells for diabetes achieved good efficacy. The application of autologous bone marrow nucleated cells in the treatment of premature ovarian failure, male sexual dysfunction, knee degeneration, femoral head necrosis and other diseases has achieved good results. Autologous bone marrow cells were preserved before chemotherapy in patients with malignant tumor, and transplanted back after chemotherapy to preserve bone marrow cells to promote bone marrow reconstruction. He has edited 10 academic monographs, obtained 13 national patents and published more than 160 papers.

Topic: BMPRP Therapy of Diabetes Mellitus

Abstract: PRP separated from bone marrow blood is called BMPRP. Bone marrow contains stem cells, so BMPRP is platelet-rich plasma containing stem cells. It can be widely used to treat a variety of diseases. There are stem cells in BMPRP. Stem cells can differentiate into many kinds of cells. BMPRP can differentiate into different cells in different environments. BMPRP can repair and replace damaged and aging islet cells.

Dr. Zhenzhen Chen, Professor

School of Life Sciences, Zhengzhou University, Zhengzhou, China

Biography: Dr. Zhenzhen Chen, Professor, PhD (or Master's) Supervisor. Main research direction: Targeted Therapy for Cancer Stem Cells. She has published multiple papers as the corresponding or first author in journals such as Neuron, J Clin Invest, Adv Sci, Nat Commun(×2), Cell Rep, Small, with a cumulative impact factor of 200 for her corresponding or first-author papers. She has got rewards such as Academic and Technical Leader from the Henan Provincial Department of Education and Outstanding Master's Degree Thesis Supervisor in Henan Province.

Topic: Triggerable Nanodrug Delivery System for Targeted Intervention in Cancer Therapy and Intestinal Homeostasis Regulation

Abstract: The triggerable nanodrug delivery system, through precise design, enables nanoparticles to intelligently respond to specific biological signals or environmental changes, thereby precisely targeting cancer stem cells to achieve efficient and low-toxicity cancer treatment. At the same time, it can also skillfully regulate intestinal microbial communities and maintain intestinal homeostasis, opening up new possibilities for improving patients' overall health status. We utilize advanced nanotechnology and bioengineering to construct these intelligent nanodrug delivery systems. They act like miniature drug factories, capable of releasing drugs at specific locations in the body as needed, significantly enhancing the targeting and efficiency of treatment. The emergence of the triggerable nanodrug delivery system not only brings new hope for cancer treatment but also provides powerful technological support for maintaining human health homeostasis and enhancing the quality of life.

Dr. Pingping Zhu, Professor

School of Life Sciences, Zhengzhou University, Zhengzhou, China

Biography: Dr. Pingping Zhu is a professor of Zhengzhou University and a recipient of the National excellent Youth Fund. He has published more than 20 SCI papers as corresponding or first authors, including Nat Immunol, Nat Cell Biol, Neuron, Nat Struct Mol Biol, J Clin Invest (2 articles) and Nat Commun (4 articles). He has long been engaged in research on the regulatory mechanisms of tumor initiation cells (cancer stem cells) and adult stem cells. He discovered the important role of immune factor IL-13 in the maintenance of intestinal stem cells and intestinal homeostasis (Nat Immunol, 2019), and he also discovered the important role and regulatory mechanism of the Rspo-Lgr4 and Atf4-Sox9 stemness pathways in ISC self-renewal (EMBO J, 2023; Nat Cell Biol, 2018) and revealed the molecular mechanism by which the neurotransmitter 5-HT regulates the stemness of intestinal stem cells through macrophages (Cell Res, 2022).

Topic: "ZNF207-TAZ" Loop Drives the Self-Renewal of Liver Cancer Stem Cells

Abstract: Liver cancer is one of the most common tumor types in the world, and is often accompanied by cirrhosis. Liver cancer stem cells are critical in liver tumorigenesis. However, how extracellular mechanical stress integrates and transforms in liver cancer stem cells to initiate tumorigenesis remains unclear. Here, we found that TAZ, but not YAP, is a necessary factor for liver cancer stem cell self-renewal, with significantly higher expression of YAP compared to TAZ in liver cancer. TAZ is regulated by ZNF207, and the expression of ZNF207 itself is also initiated by TAZ, forming a "ZNF207-TAZ" loop. Based on this, we proposed dual-activation cascades of TAZ in liver cancer stem cells. Blocking ZNF207 or TAZ inhibited self-renewal, proliferation, and metastasis of cancer stem cells in vitro. In vivo, ZNF207 knockout and TAZ knockout significantly inhibited HCC stem cell self-renewal and occurrence, while YAP knockout could not. The role of ZNF207 is dependent on TAZ but not YAP, suggesting that ZNF207-TAZ-mediated dual-activation cascades also play a key role in in vivo CSC self-renewal and liver cancer development.